675576-26-8

Basic information

• Product Name: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinoline
• Synonyms: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinoline;Isoquinoline-6-boronic acid pinacol ester;6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)ISOQUINOLINE 97%
• CAS NO: 675576-26-8
• Molecular Formula: C₁₅H₁₈BNO₂
• Molecular Weight: 255.13
• Mol File: 675576-26-8.mol
• Article Data: 8

Chemical Properties

• Melting Point: 179-184°C
• Boiling Point: 397.5°C at 760 mmHg
• Flash Point: 194.2°C
• Appearance: /
• Density: 1.10±0.1 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 3.62E-06mmHg at 25°C
• Refractive Index: 1.558
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 5.03±0.14(Predicted)
• CAS DataBase Reference: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinoline(675576-26-8)
• EPA Substance Registry System: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinoline(675576-26-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 675576-26-8(Hazardous Substances Data)

Usage

Uses

Useful boron compound for Suzuki coupling.

InChI:InChI=1/C15H18BNO2/c1-14(2)15(3,4)19-16(18-14)13-6-5-12-10-17-8-7-11(12)9-13/h5-10H,1-4H3

Upstream product

• 34784-05-9 6-bromo-isoquinoline 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 70125-61-0 6-phenylisoquinoline 
• 922718-57-8 2-methyl-6-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-1,2,3,4-tetrahydroisoquinoline 
• 922718-56-7 2-methyl-6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-isoquinolinium; iodide 
• 922718-55-6 6-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-1,2,3,4-tetrahydroisoquinoline 

Relevant articles and documents

PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g., respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), and retinopathy of prematurity (ROP).

RESORCINOL DERIVATIVE AS HSP90 INHIBITOR

The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds.

IMIDAZO [1, 2 - B] PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF

Imidazo[1,2-b]pyridazine-based compounds of the formula (I): are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.